JP2023507634A5 - - Google Patents

Info

Publication number
JP2023507634A5
JP2023507634A5 JP2022537877A JP2022537877A JP2023507634A5 JP 2023507634 A5 JP2023507634 A5 JP 2023507634A5 JP 2022537877 A JP2022537877 A JP 2022537877A JP 2022537877 A JP2022537877 A JP 2022537877A JP 2023507634 A5 JP2023507634 A5 JP 2023507634A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
dihydroisoquinoline
hydroxypiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507634A (ja
JP7589247B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064765 external-priority patent/WO2021126731A1/en
Publication of JP2023507634A publication Critical patent/JP2023507634A/ja
Publication of JP2023507634A5 publication Critical patent/JP2023507634A5/ja
Application granted granted Critical
Publication of JP7589247B2 publication Critical patent/JP7589247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537877A 2019-12-17 2020-12-14 Prmt5阻害剤 Active JP7589247B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962949242P 2019-12-17 2019-12-17
US201962949248P 2019-12-17 2019-12-17
US62/949,248 2019-12-17
US62/949,242 2019-12-17
US202063025629P 2020-05-15 2020-05-15
US63/025,629 2020-05-15
PCT/US2020/064765 WO2021126731A1 (en) 2019-12-17 2020-12-14 Prmt5 inhibitors

Publications (3)

Publication Number Publication Date
JP2023507634A JP2023507634A (ja) 2023-02-24
JP2023507634A5 true JP2023507634A5 (https=) 2023-12-20
JP7589247B2 JP7589247B2 (ja) 2024-11-25

Family

ID=76477897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537877A Active JP7589247B2 (ja) 2019-12-17 2020-12-14 Prmt5阻害剤

Country Status (11)

Country Link
US (1) US12595262B2 (https=)
EP (1) EP4077282B1 (https=)
JP (1) JP7589247B2 (https=)
KR (1) KR102915244B1 (https=)
CN (1) CN115087638B (https=)
AU (1) AU2020408148B2 (https=)
BR (1) BR112022012032A2 (https=)
CA (1) CA3160153A1 (https=)
MX (1) MX2022007535A (https=)
WO (1) WO2021126731A1 (https=)
ZA (1) ZA202206071B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
WO2022048631A1 (zh) * 2020-09-04 2022-03-10 上海翊石医药科技有限公司 一种具有抗肿瘤活性的化合物及其用途
AU2022271927B2 (en) * 2021-05-13 2025-07-10 Innovstone Therapeutics Limited Compound having anti-tumor activity and use thereof
WO2024101965A1 (ko) * 2022-11-10 2024-05-16 에스케이바이오팜 주식회사 Prmt5 저해제와 dna 손상 유도 물질의 약학적 조합물
WO2024099411A1 (zh) * 2022-11-11 2024-05-16 石药集团中奇制药技术(石家庄)有限公司 一种杂环类抗肿瘤化合物的盐及其晶型

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (https=) 1972-05-19 1975-08-18 Bofors Ab
SE378109B (https=) 1972-05-19 1975-08-18 Bofors Ab
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd 3−ヒドロキシ−ml−236b誘導体の製造法
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (en) 1993-01-15 1997-11-19 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CH690163A5 (fr) 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
EP0873123B1 (en) 1995-11-06 2003-04-09 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
JP4183099B2 (ja) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) エポチロンcおよびd、製造法ならびに組成物
JP2000500502A (ja) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
SK283335B6 (sk) 1995-12-08 2003-06-03 Janssen Pharmaceutica N. V. (Imidazol-5-yl)metyl-2-chinolinónové deriváty, spôsob a medziprodukty na ich prípravu, ich použitie a farmaceutické kompozície na ich báze
IL125062A (en) 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
AU1529997A (en) 1996-01-16 1997-08-11 Warner-Lambert Company Substituted histidine inhibitors of protein farnesyltransferase
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
ATE233743T1 (de) 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
WO1997044350A1 (en) 1996-05-22 1997-11-27 Warner-Lambert Company Inhibitors of protein farnesyl transferase
WO1998002436A1 (en) 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2276081A1 (en) 1996-12-30 1998-07-09 Lekhanh O. Tran Inhibitors of farnesyl-protein transferase
EP0951285A1 (en) 1996-12-30 1999-10-27 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU4698299A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 5-HT7 receptor antagonists
JP2002536968A (ja) 1999-01-29 2002-11-05 イムクローン システムズ インコーポレイティド Kdrに特異的な抗体およびその使用
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
WO2001070677A1 (en) 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
GB0025173D0 (en) 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
CA2427206C (en) 2000-11-02 2011-06-28 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
US6960584B2 (en) 2001-04-10 2005-11-01 Merck & Co., Inc. Inhibitors of Akt activity
US7034026B2 (en) 2001-04-10 2006-04-25 Merck & Co., Inc. Inhibitors of Akt activity
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20040106540A1 (en) 2001-04-10 2004-06-03 Barnett Stanley F Method of treating cancer
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
JP3711131B2 (ja) 2001-08-21 2005-10-26 メルク シャープ エンド ドーム リミテッド 新規のシクロヘキシルスルホン
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
CA2468156A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害剤
CA2467722A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Thienopyrimidinone derivatives as mitotic kinesin inhibitors
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
TW200302726A (en) 2002-01-31 2003-08-16 Ono Pharmaceutical Co Nitrogen-containing bicyclic compound and medicament containing same as active ingredient
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
JP4394959B2 (ja) 2002-04-08 2010-01-06 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
EP1496906A4 (en) 2002-04-08 2006-05-03 Merck & Co Inc HEMMER OF ACT ACTIVITY
EP1496981A2 (en) 2002-04-08 2005-01-19 Merck & Co., Inc. Method of treating cancer
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
EP1503998B1 (en) 2002-05-01 2009-07-01 MERCK SHARP & DOHME LTD. Heteroaryl substituted spirocyclic sufamides for inhibition of gamma secretase
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
ATE356804T1 (de) 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1515724B1 (en) 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0223040D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
WO2004037171A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP2006507299A (ja) 2002-10-30 2006-03-02 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害薬
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
CA2509212A1 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US7622489B2 (en) 2002-12-20 2009-11-24 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
ATE461179T1 (de) 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
CN1809354A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
MXPA05012323A (es) 2003-05-16 2006-01-30 Merck Sharp & Dohme Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
CA2475186C (en) 2003-07-17 2010-01-05 At&T Corp. Method and apparatus for windowing in entropy encoding
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
WO2005018638A1 (en) 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1664026B1 (en) 2003-08-15 2009-01-21 Merck & Co., Inc. Mitotic kinesin inhibitors
PE20050730A1 (es) 2003-08-15 2005-09-20 Merck & Co Inc Derivados de 2,5-dihidropirrol 2,2-disustituidos como inhibidores de quinesinas mitoticas
WO2005017190A2 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2007502773A (ja) 2003-08-15 2007-02-15 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害薬
US7514459B2 (en) 2003-09-24 2009-04-07 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
GB0323258D0 (en) 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
US7294640B2 (en) 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1737861A4 (en) 2004-04-09 2010-04-28 Merck Sharp & Dohme HEMMER OF ACT ACTIVITY
CA2561311A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
AU2006216998B2 (en) 2005-02-14 2010-12-23 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP5103604B2 (ja) 2006-10-31 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての2−アミノチアゾール−4−カルボン酸アミド
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CN102802840B (zh) 2010-01-20 2014-10-29 麦格纳国际公司 双金属部件及其制造方法
US9469615B2 (en) 2010-12-23 2016-10-18 Merck Sharp & Dohme Corp. Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
WO2016173710A1 (en) 2015-04-28 2016-11-03 Laboratorios Del Dr. Esteve, S.A. Spiro-isoquinoline-3,4'-piperidine compounds having activity against pain
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
WO2018161922A1 (zh) 2017-03-09 2018-09-13 中国科学院上海药物研究所 一种具有prmt5抑制活性的化合物及其制备和应用
GB201704327D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
US20200123147A1 (en) * 2017-06-29 2020-04-23 Bayer Aktiengesellschaft Thiazole compounds useful as prmt5 inhibitors
US10947234B2 (en) * 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) * 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
CN113330009B (zh) 2019-03-12 2024-02-09 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Similar Documents

Publication Publication Date Title
JP2023507634A5 (https=)
JP7525681B2 (ja) 7h-ピロロ[2,3-d]ピリミジンjak-阻害剤
JP2023512175A5 (https=)
AU2014272776B2 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2023512174A5 (https=)
JP2024534187A5 (https=)
JP6892448B2 (ja) 悪性腫瘍の処置の方法
CA2934137C (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
CN115243681B (zh) 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
CN109803963A (zh) 具有usp30抑制剂活性的氰基取代的杂环
JP2022105159A (ja) 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン
CN103298345B (zh) 组合
TW201026696A (en) Monocarbams
WO2017152062A1 (en) Compositions and combinations of autotaxin inhibitors
AU2018309372B2 (en) Methods of treating behavior alterations
JP5202302B2 (ja) 医薬組成物
EA031201B1 (ru) Соединения имидазопиридазина
CN111757884A (zh) 取代的大环吲哚衍生物
JP2011509306A5 (https=)
TWI323658B (en) Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
US20140341993A1 (en) Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method of production thereof
TW202340182A (zh) 做為ripk1抑制劑之異㗁唑啶及其用途
CN112839656A (zh) 急性骨髓性白血病用抗肿瘤剂
CN113330007A (zh) 尼拉帕利游离碱的晶体形式
JP2023508137A5 (https=)